ATLASBioCryst Pharmaceuticals (BCRX) earnings date: Nov 4, 2026
BioCryst Pharmaceuticals (BCRX) reports earnings for the quarter ended Sep 30, 2026 on Wed, Nov 4, 2026, before the open. Analysts expect EPS of $0.10.
Source: company filings and exchange data · Updated Nov 2, 2026
ATLAS view on BCRX
| Last price | $8.25 (-2.6%) |
|---|---|
| Normal 1-day range (±1σ) | ±2.6% |
| Earnings beat history | Beat the EPS estimate in 4 of the last 5 reports |
These figures come from the same calibrated model and valuation as the BioCryst Pharmaceuticals stock page. They describe an ordinary period, not the earnings reaction itself, which is usually wider and can go either way.
BioCryst Pharmaceuticals reports on Nov 4, 2026. One email the day before, with ATLAS’s read on BioCryst Pharmaceuticals. You can switch it off at any time.
Alert me before BCRX reportsFree to start. Creating an account takes under a minute.
Notify me when BioCryst Pharmaceuticals reports
Track BCRX free Add BioCryst Pharmaceuticals to a free ATLAS watchlist and see its next report date in one place.
BCRX earnings at a glance
| Next report (confirmed) | Wed, Nov 4, 2026 |
|---|---|
| Time | Before the open |
| Period | Quarter ended Sep 30, 2026 |
| EPS estimate | $0.10 |
| Last report | Aug 5, 2026 · Beat |
| Beat rate (last 5 reports) | 4 of 5 (80%) |
| Average EPS surprise | +25.1% |
| Average move around a report | ±5.4% (last 5) |
| Sector | Healthcare · Drug Manufacturers - Specialty & Generic |
BioCryst Pharmaceuticals earnings history: last 5 reports
BioCryst Pharmaceuticals last reported on Aug 5, 2026: EPS of $0.35 against an estimate of $0.24 (+45.8% surprise), a beat.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Aug 5, 2026 | $0.24 | $0.35 | +45.8% | Beat | +3.1% |
| Jul 28, 2026 | $0.87 | $0.89 | +2.3% | Beat | -0.5% |
| Jul 9, 2026 | $0.04 | -$0.02 | -150.0% | Miss | -5.9% |
| May 6, 2026 | $0.11 | $0.14 | +27.3% | Beat | -1.4% |
| Feb 26, 2026 | $0.07 | $0.21 | +200.0% | Beat | +15.9% |
*Move: change in the closing price from the last close before the report day to the close the day after it, so it captures the reaction whether the company reported before the open or after the close.
Get the full ATLAS analysis for BCRX
See the fair value, the probability range and the earnings history of BioCryst Pharmaceuticals on its ATLAS page.
BioCryst Pharmaceuticals (BCRX) stock analysisPlans from €3.99 a month.
BioCryst Pharmaceuticals earnings: frequently asked questions
When does BioCryst Pharmaceuticals (BCRX) report earnings?
BioCryst Pharmaceuticals is scheduled to report on Wednesday, November 4, 2026, before the open. ATLAS only shows a confirmed date when the company or the exchange data provides one; check the investor relations page for the call details.
What is the EPS estimate for BCRX?
The consensus EPS estimate for the quarter ended Sep 30, 2026 is $0.10 per share (USD). Estimates can change before the report.
How often does BCRX beat earnings estimates?
Of its last 5 reports with a recorded result, BioCryst Pharmaceuticals beat the EPS estimate 4 times; the average surprise was +25.1%. Past results do not predict the next one.
How much does BCRX move around earnings?
Over its last 5 reports the stock moved an average of 5.4% (absolute, from the close before the report day to the close after it), and finished higher 2 of 5 times.
Did BioCryst Pharmaceuticals beat earnings estimates last quarter?
BioCryst Pharmaceuticals last reported on Aug 5, 2026: EPS of $0.35 against an estimate of $0.24 (+45.8% surprise), a beat.
How much does BCRX usually move in a day?
On a normal trading day the ATLAS model puts BCRX’s one-day range at about ±2.6%, with a 50% chance of closing higher. This is not an options-implied earnings move; earnings days are usually wider.
Also reporting on Wed, Nov 4, 2026
Educational information, not investment advice. Disclaimer